Dana-Farber Cancer Institute and Brigham and Women's Hospital, both in Boston, have launched a major effort to scan tumor tissue from adult cancer patients for hundreds of gene mutations linked to cancer.
Clinicians at Dana-Farber/Brigham and Women's Cancer Center already use targeted therapies that pinpoint genetic mutations in a select number of cancers, including colon, lung, breast, and some leukemias and sarcomas.
The Profile program aims to identify a far greater number of mutations for a wider array of cancers, ultimately enabling clinicians to treat more cancers with targeted therapies in the future.
Dr. Karen Joynt of Brigham and Women's in Boston to Discuss Readmissions
Brigham and Women's Hospital CIO Sue Schade: Top Health IT Priorities
Clinicians at Dana-Farber/Brigham and Women's Cancer Center already use targeted therapies that pinpoint genetic mutations in a select number of cancers, including colon, lung, breast, and some leukemias and sarcomas.
The Profile program aims to identify a far greater number of mutations for a wider array of cancers, ultimately enabling clinicians to treat more cancers with targeted therapies in the future.
Related Articles on Brigham and Women's Hospital:
Brigham and Women's Offers Paid High School Internships to Boost Interest in HealthcareDr. Karen Joynt of Brigham and Women's in Boston to Discuss Readmissions
Brigham and Women's Hospital CIO Sue Schade: Top Health IT Priorities